Levoleucovorin and Leucovorin Agents
Customize your policy alerts
Sign up for Empire Bluecross Policy CC-0104 alerts
Get alerted when Policy CC-0104 changes without checking for updates manually.
Monitor payer policy activity
Medical-benefit clinical review and prior authorization for injectable levoleucovorin and leucovorin agents, including Khapzory and Vykoura, for methotrexate rescue or toxicity reduction, selected oncology indications, anemia, and graft-versus-host disease prophylaxis.
Added coverage criteria for Vykoura based on product labeling and NCCN recommendations.
Revised oncology criteria for levoleucovorin and leucovorin agents.
Updated step therapy to include Vykoura.
Updated ICD-10-CM diagnosis coding.
Updated HCPCS coding for Vykoura.
Removed HCPCS J0640.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.